These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 26401016)
1. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. Park H; Cho SY; Kim H; Na D; Han JY; Chae J; Park C; Park OK; Min S; Kang J; Choi B; Min J; Kwon JY; Suh YS; Kong SH; Lee HJ; Liu ET; Kim JI; Kim S; Yang HK; Lee C Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12492-7. PubMed ID: 26401016 [TBL] [Abstract][Full Text] [Related]
2. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer. Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936 [TBL] [Abstract][Full Text] [Related]
3. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer. Su Y; Lin L; Zhang J; Jiang Y; Pan C; Sun L; Duan J; Liao W Mol Med Rep; 2015 Oct; 12(4):5771-9. PubMed ID: 26239822 [TBL] [Abstract][Full Text] [Related]
4. Dihydroartemisinin inhibits the tumorigenesis and invasion of gastric cancer by regulating STAT1/KDR/MMP9 and P53/BCL2L1/CASP3/7 pathways. Liang R; Chen W; Chen XY; Fan HN; Zhang J; Zhu JS Pathol Res Pract; 2021 Feb; 218():153318. PubMed ID: 33370709 [TBL] [Abstract][Full Text] [Related]
5. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349 [TBL] [Abstract][Full Text] [Related]
7. Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems. Chang HR; Park HS; Ahn YZ; Nam S; Jung HR; Park S; Lee SJ; Balch C; Powis G; Ku JL; Kim YH BMC Cancer; 2016 Mar; 16():200. PubMed ID: 26955870 [TBL] [Abstract][Full Text] [Related]
8. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. Lim B; Kim C; Kim JH; Kwon WS; Lee WS; Kim JM; Park JY; Kim HS; Park KH; Kim TS; Park JL; Chung HC; Rha SY; Kim SY Oncotarget; 2016 Feb; 7(7):8055-66. PubMed ID: 26811494 [TBL] [Abstract][Full Text] [Related]
9. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Ali SM; Sanford EM; Klempner SJ; Rubinson DA; Wang K; Palma NA; Chmielecki J; Yelensky R; Palmer GA; Morosini D; Lipson D; Catenacci DV; Braiteh F; Erlich R; Stephens PJ; Ross JS; Ou SH; Miller VA Oncologist; 2015 May; 20(5):499-507. PubMed ID: 25882375 [TBL] [Abstract][Full Text] [Related]
10. Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer. Fan B; Dachrut S; Coral H; Yuen ST; Chu KM; Law S; Zhang L; Ji J; Leung SY; Chen X PLoS One; 2012; 7(4):e29824. PubMed ID: 22539939 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of deleted in liver cancer 1 gene on gallbladder cancer growth through induction of cell cycle arrest and apoptosis. Qin Y; Chu B; Gong W; Wang J; Tang Z; Shen J; Quan Z J Gastroenterol Hepatol; 2014 May; 29(5):964-72. PubMed ID: 24329682 [TBL] [Abstract][Full Text] [Related]
12. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer. Zhang H; Xue J; Hessler P; Tahir SK; Chen J; Jin S; Souers AJ; Leverson JD; Lam LT Mol Cancer; 2015 Jul; 14():126. PubMed ID: 26134786 [TBL] [Abstract][Full Text] [Related]
13. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Li G; Du X; Vass WC; Papageorge AG; Lowy DR; Qian X Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17129-34. PubMed ID: 21969587 [TBL] [Abstract][Full Text] [Related]
14. Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer. Kubo T; Kuroda Y; Shimizu H; Kokubu A; Okada N; Hosoda F; Arai Y; Nakamura Y; Taniguchi H; Yanagihara K; Imoto I; Inazawa J; Hirohashi S; Shibata T Carcinogenesis; 2009 Nov; 30(11):1857-64. PubMed ID: 19734198 [TBL] [Abstract][Full Text] [Related]
15. Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/β-catenin signaling pathway mutations. Yuan W; Zhang Z; Dai B; Wei Q; Liu J; Liu Y; Liu Y; He L; Zhou D Cancer; 2016 Jun; 122(11):1689-96. PubMed ID: 26998897 [TBL] [Abstract][Full Text] [Related]
16. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170 [TBL] [Abstract][Full Text] [Related]
17. Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review). Zimonjic DB; Popescu NC Int J Oncol; 2012 Aug; 41(2):393-406. PubMed ID: 22580498 [TBL] [Abstract][Full Text] [Related]
18. SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions. Tripathi BK; Anderman MF; Qian X; Zhou M; Wang D; Papageorge AG; Lowy DR J Cell Biol; 2019 Sep; 218(9):3060-3076. PubMed ID: 31308216 [TBL] [Abstract][Full Text] [Related]
19. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. Chen Z; Huang W; Tian T; Zang W; Wang J; Liu Z; Li Z; Lai Y; Jiang Z; Gao J; Shen L J Hematol Oncol; 2018 Feb; 11(1):20. PubMed ID: 29433585 [TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated restoration of expression of the tumor suppressor gene DLC1 inhibits the proliferation and tumorigenicity of aggressive, androgen-independent human prostate cancer cell lines: prospects for gene therapy. Guan M; Tripathi V; Zhou X; Popescu NC Cancer Gene Ther; 2008 Jun; 15(6):371-81. PubMed ID: 18369381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]